Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: a scoping review protocol

Seda Yerlikaya, Lydia Marie-Luise Holtgrewe, Tobias Broger, Chris Isaacs, Payam Nahid, Adithya Cattamanchi, Claudia M Denkinger

ABSTRACT

Introduction In 2014, the WHO published high-priority target product profiles (TPPs) for new tuberculosis (TB) diagnostics to align end-user needs with test targets and specifications; nevertheless, no TB test meets these targets to date. The COVID-19-driven momentum in the diagnostics world offers an opportunity to address the long-standing lack of innovation in the field of TB diagnostics. This scoping review aims to summarise point-of-care (POC) molecular and antigen tests for COVID-19 diagnosis that, when applied to TB, potentially meet WHO TPPs. This summary of currently available innovative diagnostic tools will guide the development of novel TB diagnostics toward the WHO-set targets.

Methods and analysis We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension Scoping Reviews recommendations. MEDLINE (via PubMed), bioRxiv, MedRxiv and other publicly available in vitro diagnostic test databases were searched on 23 November 2022. POC antigen or molecular tests developed for SARS-CoV-2 detection that meet the eligibility criteria will be included in the review. Developer description, test description, operation characteristics, pricing information, performance and commercialisation status of diagnostic tests identified will be extracted using a predefined standardised data extraction form. Two reviewers will independently perform the screening and data extraction. A narrative synthesis of the final data will be provided.

Ethics and dissemination No ethical approval is required because individual patient data will not be included. The findings will be published in open-access scientific journals.

INTRODUCTION

Rationale

Until COVID-19, tuberculosis (TB) was the leading single infectious cause of death in the world, responsible for approximately 10 million new cases and 1.5 million deaths each year, primarily among the most socioeconomically vulnerable.1 Delayed and missed diagnosis is a major impediment to improving individual TB outcomes and control.2-4 Every year, more than one-third of all TB cases go undiagnosed. This diagnostic gap has been further widened by COVID-19.1 Sputum smear microscopy remains the predominant TB microbiological test, despite WHO recommendations for the adoption of rapid molecular testing for TB diagnosis.5 6 The varying clinical sensitivity of smear microscopy, as well as the difficulties in obtaining sputum from patients and access to healthcare, are among the key contributors to missed TB diagnosis.7

In 2014, WHO defined four target product profiles (TPP) that were deemed of high priority: a point-of-care (POC) non-sputum-based biomarker test, a POC triage test, a POC smear microscopy replacement and a rapid drug-susceptibility test.8 The TPPs were designed to guide developers towards fit-for-purpose TB diagnostics in terms of test performance and operational characteristics. The currently available TB tests hold the promise of helping close the TB diagnostic gap, but still fall short of meeting the TPPs either due to low accuracy or limited operational suitability.8-9 The GeneXpert Dx System (Cepheid, Sunnyvale, California, USA), an integrated, single-use cartridge-based diagnostic system, has been the molecular
diagnostic test of choice for TB since its market release in 2010.10 The Xpert MTB/RIF (Xpert and Xpert MTB/RIF Ultra (Xpert Ultra) cartridges detect Mycobacterium tuberculosis (MTB) DNA along with mutations associated with rifampicin resistance, with the latter being an improved version with increased sensitivity.9 Despite its promise as a POC TB test, the system has considerable drawbacks, such as the need for continuous power, high maintenance and low operating temperatures, low specificity in individuals with a history of TB and the use of sputum as the sample type. TrueNat TB assays (Molbio Diagnostics, Bangalore, India) have lately emerged as a true POC alternative to the GeneXpert system, owing to its improved operational aspects; nonetheless, TrueNat still relies on sputum.9,11,12

The only non-sputum TB tests on the market are Alere Determine TB LAM Ag test (Abbott, Chicago, Illinois, USA) and Fujifilm SILVAMP TB LAM assay (FujiFilm, Tokyo, Japan). Both tests are lateral flow assays (LFA) that detect lipoarabinomannan (LAM), a component of mycobacterial cell wall, in urine. They are best suited for use in resource-constrained settings due to their quick turnaround time (less than 30 min), instrument-free operation and minimal training needs.12 However, these rapid tests show reasonable performance only in specific populations (eg, people living with HIV) and require a confirmatory test due to their suboptimal specificity.13,14 The limit of detection (LoD) of a rapid, low-cost POC LAM detection test capable of detecting TB in all patient groups and meeting the WHO TPP is estimated to be 5 pg/mL, compared with the current tests’ LoD of >25 pg/mL.15 As a result, instrument-based, high-sensitivity antigen detection systems are more likely than conventional LFAs to hit this target.

The desire to gain a share of the COVID-19-generated diagnostic market drove developers to innovate and speed up their development pipelines over the last 2 years. As the market reaches saturation, developers are looking for new avenues to apply their innovations. TB would be a viable option for these developers, given the extremely high disease burden, supportive government initiatives, lower validation costs thanks to no-cost TB clinical platforms (eg, R2D2 TB Network, END-TB) and economies of scale resulting from a large available market despite the low margin. It is critical to identify promising innovations early on and connect their developers with assay developers and other key stakeholders in order to capitalise on the COVID-19-driven momentum.

**Objectives**

In this scoping review, we will summarise POC molecular and antigen tests for COVID-19 diagnosis with the potential of meeting the WHO TPPs for new TB diagnostics. This summary of currently available innovative diagnostic tools will aid the development of novel TB diagnostics to meet WHO TPP targets by informing developers, funders of TB diagnostic tools and also advocates for access to TB diagnostic testing.

**METHODS**

**Overview**

This is a scoping review of the scientific literature and COVID-19 test databases. This protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA) guidelines,16 and the methodological framework developed by Levac et al.17 The final publication of this study will follow the PRISMA extension Scoping Reviews (PRISMA-ScR) recommendations.18

In this review, we aim to address which innovative diagnostic tools developed for COVID-19, if successfully applied to TB, may fulfill the WHO TPPs of TB diagnostics for use in high TB burden settings. The focus will be on POC molecular and antigen tests.

**Definitions**

For this work, we will follow the following definitions:

► Diagnostic test: ‘a test that is used to determine, verify or confirm a patient’s clinical condition as a sole determinant’.19
► POC in vitro diagnostic (IVD) testing: ‘testing that can be performed by a lay user or a minimally trained healthcare professional at home and/or near a patient and outside of central laboratory testing facilities and can result in an immediate decision for next steps of care’.20
► TPPs that define high priority development targets for new tests, specifying performance and operational characteristics and the cost range of desired new tests.8

**Eligibility criteria**

We will include all POC antigen or molecular tests developed and used for SARS-CoV-2 detection that meet the inclusion criteria outlined below, which were adapted from the Cochrane review by Dinnes et al.21

► Portable or easily transportable equipment for running and/or reading the assay (mains-/battery-powered).
► Minimal sample preparation requirements (eg, single-step mixing, no requirement for additional equipment or precise sample volume transfer unless a disposable automatic fill or graduated transfer device is used).
► Minimal biosafety requirements (eg, personal protective equipment, good ventilation and a biohazard bag for waste disposal).
► No requirement for a temperature-controlled environment.
► Test results available within a single clinical encounter (less than 2 hours of sample collection).22

We will include studies of all designs, as well as case reports, reviews, letters and editorials, which use or report on a POC molecular or antigen test for
<table>
<thead>
<tr>
<th>Condition of Interest</th>
<th>Items found</th>
</tr>
</thead>
</table>

**Table 1** Search strategy

**PubMed/MEDLINE (searched on 23 November 2022)**

<table>
<thead>
<tr>
<th>Condition of Interest</th>
<th>Items found</th>
</tr>
</thead>
</table>

**medRxiv (searched on 23 Nov 2022)**

<table>
<thead>
<tr>
<th>Condition of Interest</th>
<th>Items Found</th>
</tr>
</thead>
</table>

**Intended Setting**

<table>
<thead>
<tr>
<th>Case</th>
<th>Items Found</th>
</tr>
</thead>
</table>

**Intended Use**

<table>
<thead>
<tr>
<th>Case</th>
<th>Items Found</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;diagnos&quot;, &quot;detect&quot;</td>
<td>10915</td>
</tr>
</tbody>
</table>

**Search Term**

<table>
<thead>
<tr>
<th>PubMed/MEDLINE (searched on 23 November 2022)</th>
<th>Items Found</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;2019 nCoV&quot; OR &quot;2019nCoV&quot; OR &quot;2019 novel coronavirus&quot; OR &quot;COVID-19&quot; OR &quot;covid-19&quot; OR &quot;COVID19&quot; OR &quot;covid 19&quot; OR &quot;new coronavirus&quot; OR &quot;novel coronavirus&quot; OR &quot;novel corona virus&quot; OR &quot;sars cov 2&quot; OR &quot;SARS-CoV-2&quot; OR &quot;severe acute respiratory syndrome coronavirus 2&quot;) AND (&quot;molecular&quot; OR &quot;isothermal&quot; OR &quot;PCR&quot; OR &quot;polymerase chain reaction&quot; OR &quot;LAMP&quot; OR &quot;immunoassay&quot; OR &quot;antigen&quot; OR &quot;CRISPR&quot;) AND (&quot;point of care&quot; OR &quot;POC&quot; OR &quot;near patient&quot; OR &quot;rapid test&quot; OR &quot;bedside test&quot; OR &quot;laboratory-independent&quot; OR &quot;point-of-care&quot; OR &quot;POCT&quot; OR &quot;portable&quot;) AND (&quot;diagnos&quot; OR &quot;detect&quot;)</td>
<td>275</td>
</tr>
</tbody>
</table>

**bioRxiv (searched on 23 Nov 2022)**

<table>
<thead>
<tr>
<th>Condition of Interest</th>
<th>Items Found</th>
</tr>
</thead>
</table>

**Intended Setting**

<table>
<thead>
<tr>
<th>Case</th>
<th>Items Found</th>
</tr>
</thead>
</table>

**Intended Use**

<table>
<thead>
<tr>
<th>Case</th>
<th>Items Found</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;diagnos&quot;, &quot;detect&quot;</td>
<td>25150</td>
</tr>
</tbody>
</table>

**Search Term**

<table>
<thead>
<tr>
<th>bioRxiv (searched on 23 Nov 2022)</th>
<th>Items Found</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;2019 nCoV&quot; OR &quot;2019nCoV&quot; OR &quot;2019 novel coronavirus&quot; OR &quot;COVID-19&quot; OR &quot;covid-19&quot; OR &quot;COVID19&quot; OR &quot;covid 19&quot; OR &quot;new coronavirus&quot; OR &quot;novel coronavirus&quot; OR &quot;novel corona virus&quot; OR &quot;sars cov 2&quot; OR &quot;SARS-CoV-2&quot; OR &quot;severe acute respiratory syndrome coronavirus 2&quot;) AND (&quot;molecular&quot; OR &quot;isothermal&quot; OR &quot;PCR&quot; OR &quot;polymerase chain reaction&quot; OR &quot;LAMP&quot; OR &quot;immunoassay&quot; OR &quot;antigen&quot;) AND (&quot;point of care&quot; OR &quot;POC&quot; OR &quot;near patient&quot; OR &quot;rapid test&quot; OR &quot;bedside test&quot; OR &quot;laboratory-independent&quot; OR &quot;point-of-care&quot; OR &quot;POCT&quot; OR &quot;portable&quot;) AND (&quot;diagnos&quot; OR &quot;detect&quot;)</td>
<td>33</td>
</tr>
</tbody>
</table>

**Information sources**

We will search for peer-reviewed published scientific literature in PubMed/Medline and preprints in bioRxiv and MedRxiv. In addition, the following sources will be searched:


SARS-CoV-2 detection. No restrictions on language or date will be applied. Translations will be carried out using Google Translate or DeepL as necessary. We will exclude diagnostic tests that meet the following exclusion criteria:

- Conventional lateral flow assay without any innovative features for improved performance.
- Open system molecular assays.
- Tests that are currently in use for TB.


Table 2 Data extraction strategy

<table>
<thead>
<tr>
<th>Developer description</th>
<th>Developer name, business type, website, country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test description</td>
<td>Product name, technology type, technology description, primary use case, target population, technology readiness/maturity level, target end user, target setting</td>
</tr>
<tr>
<td>Operation characteristics</td>
<td>Sample type, number of manual sample processing steps, biomarker target, multiuse platform, throughput capacity, time-to-result, hands-on-time, ease of use, infrastructure requirements, operating temperature, operating humidity level, shelf life, connectivity, biosafety</td>
</tr>
<tr>
<td>Pricing</td>
<td>Estimated price range per test, estimated price range per instrument</td>
</tr>
<tr>
<td>Performance</td>
<td>Limit of detection, diagnostic sensitivity, diagnostic specificity</td>
</tr>
<tr>
<td>Commercialisation status</td>
<td>Current regulatory status</td>
</tr>
</tbody>
</table>


Search strategy

The search term used is shown in table 1. The search term will be adapted as necessary for the other databases. The medrxiv package in R (V.4.0.5; R Foundation for Statistical Computing) is used to search the bioRxiv and MedRxiv databases to overcome the limitations of the search functionality of these websites and allow for reproducibility.

Study records

All retrieved articles will be collated using the Covidence software and duplicates will be removed. The same software will be used for screening. Two reviewers will independently screen the titles and abstracts of the initial search results against the eligibility criteria. Following that, full-text screening will be performed by the same reviewers using standardised forms on Covidence. Any discrepancies that arise during the screening will be resolved through consensus or by a third reviewer.

Data collection process

Covidence will also be used for data extraction. Developer description, test description, operation characteristics, pricing information, performance and commercialisation status will be extracted based on the predefined variables (table 2). One reviewer will extract data from the selected reports, which will then be reviewed by a second reviewer. Any discrepancies will be resolved through consensus or by a third party. At this step, additional information sources, such as the developer’s website or the developer contact person, will be reviewed for each test included in the review to acquire any missing or additional data on the test of interest.

Risk of bias in individual studies

Risk of bias in individual studies will not be assessed because this is a scoping review aiming to summarise diagnostic innovations developed for COVID-19 diagnosis that could potentially meet the WHO TPPs and be deployed in low- and middle-income countries (LMICs) for TB diagnosis.

Data synthesis

Given the scope of the study, only a narrative synthesis will be provided. Information will be presented in the text and tables to summarise and explain key characteristics of the tests included, in accordance with current recommendations for scoping reviews and evidence mapping.

Study status

The literature searches were run on 23 November 2022, as outlined above. The two reviewers are currently performing screening in line with the protocol. We plan to finalise the study by July 2023 for publication.

Strengths

Our study has several strengths. Our search strategy is based on a solid framework and will involve multiple sources of information. We hope to find technologies from a wide range of developers, from academics to start-ups to large-scale IVD diagnostic companies, by searching both literature and IVD medical device databases. Two reviewers will work independently on the screening process.
Limitations
There are several limitations to our study. First, we will not attempt to search literature databases like Web of Science or Embase, preferring to focus on late-stage products that can be quickly adapted to TB. Second, we limited our search to IVD medical device databases to those that were publicly available and thus limited to high-income countries. This raises the possibility of a narrow focus on technologies developed in LMICs. We will try to address this by looking through databases from FIND and John Hopkins, which any developer from anywhere in the world can submit to. Finally, the data will be extracted by a single reviewer, but the extracted data will be reviewed by a second reviewer.

ETHICS AND DISSEMINATION
This scoping review will not require ethical approval because it does not involve individual patient data and uses sources that are in the public domain. We intend to publish our findings in open access scientific journals.

Contributors SY developed the scoping review protocol. LM-LH, TB, CI, PN, AC and CD provided critical editing and review.

Funding This systematic review is funded by the National Institutes of Health (NIH) (funding reference number U01AI152087; Rapid Research in Diagnostics Development for Tuberculosis Network).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID
Lydia Marie-Luise Holtgreve http://orcid.org/0000-0003-3692-0469

REFERENCES